HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Tighter Targeting For GMP Inspections Still Leaves Consistency Gap

This article was originally published in The Rose Sheet

Executive Summary

The number of facilities inspected for compliance with supplement GMP requirements is increasing annually as the agency meets targets set by FSMA, according to data the American Herbal Products Association presented during a webinar.

You may also be interested in...



Form 483s: Supplement Firms' Stage For Changing FDA Inspectors' Views

Firms responding proactively to an FDA form 483 on GMP violations can ward off warning letters, say lawyers familiar with FDA inspections. Evidence of changes to standard operating procedures, detailed documentation and even photographs of changes in a facility can impact FDA’s next move.

FSMA Re-inspection Fees MIA As Waiver Guidance Remains AWOL

FDA will bill supplement and conventional food product firms $248 per hour for re-inspections in the US and $285 per hour outside the country in fiscal 2018, but as it has since Congress passed FSMA, the agency will not collect re-inspection and mandatory recall fees.

FDA 'Program Alignment' Means Inspections Consistency To Supplement Industry

Reports are common about ORA officials not being knowledgeable about the agency's supplement manufacturing and marketing regulations or familiar with the commodity of dietary supplements, but relying on drug or food product manufacturing regulations when they inspect supplement facilities.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel